Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 4
2005 3
2006 11
2007 6
2008 3
2009 4
2010 5
2011 9
2012 4
2013 10
2014 3
2015 6
2016 6
2017 5
2018 5
2019 6
2020 5
2021 6
2022 9
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T. Marchetti M, et al. Among authors: silver rt. Lancet Haematol. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1. Lancet Haematol. 2022. PMID: 35358444 Review.
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Among authors: silver rt. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. Among authors: silver rt. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. N Engl J Med. 2012. PMID: 22375971 Free PMC article. Clinical Trial.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. Mascarenhas J, et al. Among authors: silver rt. Blood. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743. Blood. 2022. PMID: 35007321 Free PMC article. Clinical Trial.
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Yacoub A, et al. Among authors: silver rt. Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428. Blood. 2019. PMID: 31515250 Free PMC article. Clinical Trial.
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA. Harrison CN, et al. Among authors: silver rt. Am J Hematol. 2020 Jun;95(6):594-603. doi: 10.1002/ajh.25777. Epub 2020 Apr 17. Am J Hematol. 2020. PMID: 32129512 Free PMC article. Clinical Trial.
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators. Verstovsek S, et al. Among authors: silver rt. J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z. J Hematol Oncol. 2017. PMID: 28228106 Free PMC article. Clinical Trial.
Management of CML-blast crisis.
Hehlmann R, Saußele S, Voskanyan A, Silver RT. Hehlmann R, et al. Among authors: silver rt. Best Pract Res Clin Haematol. 2016 Sep;29(3):295-307. doi: 10.1016/j.beha.2016.10.005. Epub 2016 Oct 20. Best Pract Res Clin Haematol. 2016. PMID: 27839570 Review.
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Harrison CN, et al. Among authors: silver rt. Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8. Lancet Haematol. 2017. PMID: 28602585 Free PMC article. Clinical Trial.
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, De Stefano V, Caramella M, Salmoiraghi S, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Ruggeri M, Silver RT, Albano F, Benevolo G, Ross DM, Della Porta MG, Devos T, Rotunno G, Komrokji RS, Casetti IC, Merli M, Brociner M, Caramazza D, Auteri G, Barbui T, Cattaneo D, Bertù L, Arcaini L, Vannucchi AM, Passamonti F. Mora B, et al. Among authors: silver rt. Leukemia. 2022 Oct;36(10):2453-2460. doi: 10.1038/s41375-022-01673-3. Epub 2022 Aug 30. Leukemia. 2022. PMID: 36042316
110 results